OCGN · Ocugen, Inc.
$1.30
-0.01 (-0.76%)
At close · Aug 5
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these factors, together with the anticipated continued spending that will be necessary to continue to research, develop, and commercialize the Company's product candidates, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed May 8, 2026
Market Cap
$423.15M
Shares
338.52M
Ocugen, Inc. Earnings Call Transcripts
Every quarterly earnings call for Ocugen, Inc. (OCGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$1.01M
−$11.92M
'24 Q1
24-05-14
·
$1.14M
−$15.28M
'24 Q2
24-08-08
·
$1.14M
−$12.97M
'24 Q3
24-11-08
·
$764,000
−$13.88M
'24 Q4
25-03-05
▲46.1%
$1.48M
−$15.35M
'25 Q1
25-05-09
▲20.3%
$1.37M
−$14.74M
'25 Q2
25-08-01
▲54.2%
$1.75M
−$20.05M
'25 Q3
25-11-05
▼125.3%
$
−$17.71M
'25 Q4
26-03-04
LATEST
▲3.5%
$1.53M
−$19.18M
'26 Q1
26-05-05
Conference
Investor event
2026-06-04
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Ocugen, Inc. Q1 FY2026 Earnings Call
Confident tone
OCU400 for retinitis pigmentosa (RP)
Clinical milestones and timeline catalysts
OCU410ST for Stargardt disease
Revenue
$1.53M
▲ 3.5% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Ocugen, Inc. Q4 FY2025 Earnings Call
Confident tone
OCU410 (GA) Phase 2 data and Phase 3 initiation
Rolling BLA submission for OCU400 in 2026
OCU400 Phase 3 Limelight trial enrollment complete
Revenue
$*
▼ 125.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Ocugen, Inc. Q3 FY2025 Earnings Call
Confident tone
OCU400 Phase 3 retinitis pigmentosa
Clinical trial enrollment and timelines
OCU410 geographic atrophy / dry AMD
Revenue
$1.75M
▲ 54.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Ocugen, Inc. Q2 FY2025 Earnings Call
Revenue
$1.37M
▲ 20.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Ocugen, Inc. Q1 FY2025 Earnings Call
Confident tone
OCU410 dry AMD / geographic atrophy
OCU400 RP gene therapy program
Regulatory alignment with FDA and EMA
Revenue
$1.48M
▲ 46.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
Ocugen, Inc. Q4 FY2024 Earnings Call
Confident tone
OCU410 Dry AMD / Geographic Atrophy
OCU410ST Stargardt Disease
OCU400 Retinitis Pigmentosa Phase 3
Revenue
$764,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Ocugen, Inc. Q3 FY2024 Earnings Call
Confident tone
OCU410 for Geographic Atrophy (ArMaDa Trial)
OCU410ST for Stargardt Disease (GARDian Trial)
OCU400 Phase 3 liMeliGhT Clinical Trial for RP
Revenue
$1.14M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ocugen, Inc. Q2 FY2024 Earnings Call
Confident tone
OCU400 Phase 3 RP program
OCU410 geographic atrophy / dry AMD
Expanded Access Program for RP
Revenue
$1.14M
Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Ocugen, Inc. Q1 FY2024 Earnings Call
Confident tone
OCU400 Phase III liMeliGhT trial for RP/LCA
OCU410/Ocu410ST for dry AMD and Stargardt
Cell therapy platform and NeoCart
Revenue
$1.01M
Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-09
Ocugen, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-22
Ocugen, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Ocugen, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Ocugen, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Ocugen, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Ocugen, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Ocugen, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-25
Ocugen, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ocugen, Inc. Q3 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Ocugen, Inc. Q2 FY2021 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Ocugen, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-18
Ocugen, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-14
Ocugen, Inc. Q2 FY2020 Earnings Call
Revenue
$42,620
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-27
Ocugen, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–24 of 24 earnings calls
Key facts
CIK
1372299
CUSIP
67577C105
13F (30d)
34 filings
34 filers
Visit website
Investor relations